Episode Details
What you’ll get out of this episode:
- Discussion on the innovative non-invasive test for colorectal cancer.
- Insights into the technology behind Geneoscopy’s breakthrough.
- Implications for the future of gastrointestinal health.
Watch
Listen
Read
Introduction to Genoscopy’s Innovation
In a recent episode of the Slice of Healthcare podcast, host Jared S. Taylor sat down with Andrew Barnell, CEO of Geneoscopy, to discuss their latest medical breakthrough – a non-invasive colorectal cancer test. This revolutionary development promises to transform gastrointestinal healthcare.
Andrew Barnell: The Visionary Behind Geneoscopy
Andrew’s journey began in financial services, focusing on healthcare investment banking. His transition from finance to healthcare innovation exemplifies a passion for making a tangible impact on health outcomes.
The Mission: Improving GI Health Diagnostics
Geneoscopy’s mission centers on addressing the underserved area of gastrointestinal health diagnostics. With the goal of using human RNA isolation technology from stool samples, Geneoscopy aims to empower patients and providers in improving GI health.
A Breakthrough in Colorectal Cancer Screening
Colorectal cancer, being the second deadliest cancer globally, is often diagnosed in late stages. Geneoscopy’s test demonstrates a significant leap in early detection, boasting a 94.4% sensitivity for detecting colorectal cancer and 46% for advanced adenomas.
The Role of LabCorp and FDA Approval
In a strategic collaboration with LabCorp, Geneoscopy is poised to bring this test to market upon FDA approval. This partnership is crucial for integrating the test into clinical practice and ensuring widespread accessibility.
The Future of GI Care and Geneoscopy’s Role
Looking ahead, Geneoscopy is set to tackle other GI challenges, like inflammatory bowel disease, bringing precision medicine to the forefront of GI healthcare.
Conclusion: A New Era in GI Healthcare
Geneoscopy’s non-invasive colorectal cancer test is not just a medical advancement; it’s a beacon of hope for millions at risk of this deadly disease. The future of GI health is brighter with Geneoscopy’s commitment to innovation and patient care.
WORD FROM OUR SPONSORS:
Our sponsors for this episode are Sage Growth Partners and Quantum Health
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Quantum Health is an award-winning consumer healthcare navigation company that delivers an unparalleled consumer experience based on empathy and trust, enabling employers to achieve industry-leading satisfaction rates and independently validated claim savings. Launched in 1999, Quantum Health’s model is based on years of consumer research and the insights learned from guiding millions of consumers and their providers through their healthcare journey. Visit: https://quantum-health.com/ and follow Quantum health on social media – @Quantum Health
To learn more about our guest and their company please use the links below:
– Guest’s LinkedIn– LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
